{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.3","upperLimit":"12.1","value":"11.9"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"18.0","value":"17.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"Time to response was defined as the time from the start of treatment until the first documented evidence of CR (the disappearance of all target and non-target lesions) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD), whichever comes first. CR and PR were evaluated by an independent review per RECIST, Version 1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Only those participants who experienced either a confirmed CR or a PR were analyzed.","reportingStatus":"POSTED","timeFrame":"From randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 39 months","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"Weeks"}